Riskpilot← Back to searchSign inGet full accessFARMISAN ApS
APSActiveCVR 19659593Sømandshvile Park 25Manufacture of perfumes and toilet preparations · NACE 2042Est. 19963 employeeswww.farmisan.dk
Revenue 2024
DKK 2,3M
+288% vs 2023
EBITDA margin
88.7%
+1147% vs 2023
Equity ratio
23.9%
Financial strength
Net profit 2024
DKK 1,9M
+979% vs 2023
| Revenue | DKK 2,3M | +288% |
| EBITDA | DKK 2M | +1147% |
| Net profit | DKK 1,9M | +979% |
| Total assets | DKK 2,8M | +80% |
| Equity | DKK 674K | +156% |
| Employees | 3 | — |
Legal name
FARMISAN ApS
CVR number
19659593
Legal form
Anpartsselskab
NACE code
2042 · Manufacture of perfumes and toilet preparations
Founded
15. november 1996
Share capital
DKK 126.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at producere og drive handel med kosmetik og hudplejeprodukter og anden dermed beslægtet virksomhed.
Address
Sømandshvile Park 25
Phone
+4539650075
Email
info@farmisan.dk
Website
www.farmisan.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -127 | -65 | -80 | 265 | 363 | 5 | 3 | -169 | 385 | 501 | 659 | 594 | 2.306 |
| Staff expenses | -0 | -292 | -557 | -273 | -52 | -0 | -0 | -4 | -9 | -0 | -248 | -246 | -248 |
| EBITDA | -127 | -357 | -637 | -8 | 1.259 | -125 | -1.146 | -173 | 376 | 501 | 411 | -195 | 2.045 |
| Depreciation & amort. | 3 | -3 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -130 | -359 | -637 | -8 | 1.259 | -125 | -1.146 | -173 | 376 | 501 | 411 | -195 | 2.045 |
| Net financials | -29 | -31 | -306 | -33 | -162 | 10 | -76 | -39 | 3 | -40 | 188 | -18 | -5 |
| Profit before tax | -159 | -390 | -943 | -41 | 1.097 | -114 | -1.222 | -212 | 379 | 461 | 110 | -213 | 2.040 |
| Tax | -39 | -0 | -0 | -287 | 355 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 168 |
| Net profit | -120 | -390 | -943 | 247 | 742 | -114 | -1.222 | -212 | 379 | 461 | 110 | -213 | 1.872 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 774 | 1.181 | 878 | 1.622 | 1.961 | 1.807 | 555 | 450 | 921 | 1.629 | 1.774 | 1.566 | 2.825 |
| Equity | -41 | -431 | -1.374 | -1.128 | -386 | -500 | -1.722 | -1.934 | -1.556 | -1.095 | -985 | -1.198 | 674 |
| Long-term debt | 0 | 302 | 941 | 0 | 0 | 1.402 | 1.402 | 1.000 | 500 | 1.205 | 1.105 | 1.005 | 605 |
| Short-term debt | 815 | 1.310 | 1.312 | 2.750 | 2.347 | 905 | 875 | 1.385 | 1.976 | 1.519 | 1.654 | 1.758 | 1.546 |
| Total debt | 815 | 1.612 | 2.253 | 2.750 | 2.347 | 2.307 | 2.277 | 2.385 | 2.476 | 2.724 | 2.759 | 2.763 | 2.151 |
EBITDA margin
88.7%
This company
15.8%
Market median
+461% vs market
20122024
Equity ratio
23.9%
This company
38.2%
Market median
-37% vs market
20122024
Return on equity
277.7%
This company
18.4%
Market median
+1409% vs market
20122024
Net profit margin
81.2%
This company
8.1%
Market median
+902% vs market
20122024
Asset turnover
0.82×
This company
1.12×
Market median
+27% vs market
20122024
Debt / equity
3.19×
This company
0.62×
Market median
-415% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JW Founder | Founder | 1996 | — | — |
HS Audit | Audit | 2003 | — | — |
JK Audit | Audit | 1996 | — | — |
SM Chief Executive Officer | Chief Executive Officer | 2011 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2011 | — | — | |
| Board of Directors | 2011 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
HELSEFARMA ApS | Company | 50.0% | 50.0% | 2016 |
| Individual | 33.3% | 33.3% | 2016 | |
GREVINDE B. AHLEFELDT-LAURVIG INVEST ApS | Company | 33.3% | 33.3% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HELSEFARMA ApS
FARMISAN ApS Board members of FARMISAN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jørgen Warming | Founder | 0 companies |
| Henning Siemsen | Audit | 0 companies |
| Jan Kjærsgaard | Audit | 0 companies |
| Steffen Møller | Chief Executive Officer | 0 companies |
| Birger Bülow | Board of Directors | 0 companies |
| Annette Bülow | Board of Directors | 0 companies |
| Dorit Møller | Board of Directors | 0 companies |